Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 1

Conditions

Breast Neoplasms 18Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 6Neoplasms 3Melanoma 3Brain Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Colorectal Neoplasms 2Advanced Cancer 2Urologic Neoplasms 1Unilateral Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Multiple Myeloma 1

Interventions

Rituximab 134Cyclophosphamide 126Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 71Filgrastim 62Etoposide 56Bortezomib 44Vincristine 43Mycophenolic Acid 43Whole-Body Irradiation 42Cytarabine 42Cyclosporine 41Melphalan 38Doxorubicin 37Radiotherapy 36Busulfan 35ibrutinib 34Tacrolimus 34Methotrexate 33Prednisone 32Lenalidomide 30Bendamustine Hydrochloride 30Antilymphocyte Serum 27Dexamethasone 26Carmustine 26Granulocyte Colony-Stimulating Factor 23ibritumomab tiuxetan 20sargramostim 17fludarabine 17Methylprednisolone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Mantle-Cell × abemaciclib × Clear all
NCT01739309 2023-09-21

Study of LY2835219 for Mantle Cell Lymphoma

Eli Lilly and Company

Phase 2 Completed
28 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡